Gland Pharma Limited (gland) Reports Record Revenues and Profitability Consolidated Q4 FY26: 22% Yoy Growth in Revenue and 97% PAT Growth

Gland Pharma Limited (NSE: GLAND) reports record revenues and profitability with 22% YoY growth in Q4 FY26 and 97% PAT growth.